Venaxis appoints former Pfizer executive to Board of directors
pharmafile | April 19, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Pfizer, venaxis, williams
Diganostic firm Venaxis has appointed SomaLogic’s chief medical officer Stephen Williams to the company’s Board of directors.
Williams brings his experience in diagnostic imaging and biomarker discovery to Venaxis. Steve Lundy, president and chief executive of Venaxis, said: “We are happy to welcome Steve to our Board and look forward to the benefit of his deep experience, both in diagnostic imaging, which is relevant to our market development and commercial strategy for the APPY1 Test, as well as in clinical biomarker validation, which will be instrumental to us in our evaluation and development of future Venaxis products.”
Williams joined SomaLogic in 2009 as chief medical officer. Prior to his time at SomaLogic, Williams trained as a physician at Charing Cross and Westminster Medical School, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology.
He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. In 1989 he joined Pfizer UK in experimental medicine and worked on a variety of programmess including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin].
He moved to the US in 1993 with Pfizer and worked on programmess in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was named vice president in 2006.
Williams served on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering from 2004-2007, and the executive Committee of the Biomarkers Consortium run by the Foundation for NIH from 2005-2007. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase III trials.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
